Global Arthritis Drug Market Growth 2023-2029

Global Arthritis Drug Market Growth 2023-2029

Arthritis is condition that causes pain and inflammation in joints. Around 100 different types of arthritis related conditions present globally and it is one of the leading cause of disability worldwide. The most common types of arthritis includes: Psoriatic Arthritis, Rheumatoid Arthritis, Osteoarthritis, are among others.

LPI (LP Information)' newest research report, the “Arthritis Drug Industry Forecast” looks at past sales and reviews total world Arthritis Drug sales in 2022, providing a comprehensive analysis by region and market sector of projected Arthritis Drug sales for 2023 through 2029. With Arthritis Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Arthritis Drug industry.

This Insight Report provides a comprehensive analysis of the global Arthritis Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Arthritis Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Arthritis Drug market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Arthritis Drug and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Arthritis Drug.

The global Arthritis Drug market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

Growing burden of incidence of osteoarthritis, psoriatic arthritis and rheumatoid arthritis patients are major factors driving the growth of global arthritis drugs market. According to CDC estimation from 2010-2012, about 52.5 million US adults had some form of arthritis conditions among them persons with age 65 or older reported higher prevalence of arthritis conditions than the other ages due to “wear and tear” on the joints. However, due to lack of proper medication to cure arthritis and higher cost of the medications are hindering the growth of this market over the forecast period.

This report presents a comprehensive overview, market shares, and growth opportunities of Arthritis Drug market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type
Synthetic DMARDs
Biological DMARDs
NSAIDs
Corticosteroids
Analgesics

Segmentation by application
Retail Pharmacies
Hospital Pharmacies
Drug Stores
E-Commerce

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Novartis
Eli Lilly
Celltrion
F. Hoffmann-La Roche
Pfizer
Johnson & Johnson
GSK

Key Questions Addressed in this Report

What is the 10-year outlook for the global Arthritis Drug market?

What factors are driving Arthritis Drug market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Arthritis Drug market opportunities vary by end market size?

How does Arthritis Drug break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?

Please note: The report will take approximately 2 business days to prepare and deliver.